SavedAdd your journal

Journals / Molecular Oncologic Imaging / 2023 / Cilt: 3 Sayı: 2

The Use and Advantage of E-PSMA: The EANM Standardized Reporting Guideline v1.0 in Different Prostate Cancer Patients

Pelin Özcan KARA
Zehra Pınar KOÇ
Emel CEYLAN GÜNAY
Zeynep SELCAN SAĞLAM
Gökçe YAVAN
Pages
17–24
Publication Date
2023-09-13
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The aim of this study was to evaluate 68 Ga PSMA PET-CT imaging in initial staging-first line imaging of prostate cancer from low to high risk patients based on standard reporting system with E PSMA molecular staging.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Imaging plays an important role in the evaluation of prostate cancer patients.
📊
Key Findings & Data:In recent years, much attention has been focused on 68Ga-PSMA PET-CT in prostate cancer patients and has been widely used for staging, especially biochemical relapse-restaging and therapy response for these patients.
💡
Conclusion & Impact:The aim of this study was to evaluate 68 Ga PSMA PET-CT imaging in initial staging-first line imaging of prostate cancer from low to high risk patients based on standard reporting system with E PSMA molecular staging.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:E-PSMA · PET-CT · Prostate cancer

Abstract

Imaging plays an important role in the evaluation of prostate cancer patients. In recent years, much attention has been focused on 68Ga-PSMA PET-CT in prostate cancer patients and has been widely used for staging, especially biochemical relapse-restaging and therapy response for these patients. The aim of this study was to evaluate 68 Ga PSMA PET-CT imaging in initial staging-first line imaging of prostate cancer from low to high risk patients based on standard reporting system with E PSMA molecular staging.

🔖

Cite This Article

KARA, P. Ö., KOÇ, Z. P., GÜNAY, E. C., SAĞLAM, Z. S., YAVAN, G. (2023). The Use and Advantage of E-PSMA: The EANM Standardized Reporting Guideline v1.0 in Different Prostate Cancer Patients. Molecular Oncologic Imaging, Cilt: 3 Sayı: 2, 17–24. https://ajindex.com/articles/961827

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. P Perera, M., Papa, N., Christidis, D., Wetherell, D., Hofman, M. S., Murphy, D. G., Bolton, D., & Lawrentschuk, N. (2016).
  2. Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. European urology, 70(6), 926–937. https://doi.org/10.1016/j.eururo.2016.06.021
  3. Mottet, N., Bellmunt, J., Bolla, M., Briers, E., Cumberbatch, M. G., De Santis, M., Fossati, N., Gross, T., Henry, A. M., Joniau, S., Lam, T. B., Mason, M. D., Matveev, V. B., Moldovan, P. C., van den Bergh, R. C. N., Van den Broeck, T., van der Poel, H. G., van der Kwast, T. H., Rouvière, O., Schoots, I. G., … Cornford, P. (2017). EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. European urology, 71(4), 618–629. https://doi.org/10.1016/j.eururo.2016.08.003
  4. Heidenreich, A., Bastian, P. J., Bellmunt, J., Bolla, M., Joniau, S., van der Kwast, T., Mason, M., Matveev, V., Wiegel, T., Zattoni, F., Mottet, N., & European Association of Urology (2014). EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. European urology, 65(1), 124–137. https://doi.org/10.1016/j.eururo.2013.09.046
  5. Maurer, T., Gschwend, J. E., Rauscher, I., Souvatzoglou, M., Haller, B., Weirich, G., Wester, H. J., Heck, M., Kübler, H., Beer, A. J., Schwaiger, M., & Eiber, M. (2016). Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. The Journal of urology, 195(5), 1436–1443. https://doi.org/10.1016/j.juro.2015.12.025
  6. Dewes, S., Schiller, K., Sauter, K., Eiber, M., Maurer, T., Schwaiger, M., Gschwend, J. E., Combs, S. E., & Habl, G. (2016). Integration of (68)Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study. Radiation oncology (London, England), 11, 73. https://doi.org/10.1186/s13014-016-0646-2
  7. Shakespeare T. P. (2015). Effect of prostate-specific membrane antigen positron emission tomography on the decision-making of radiation oncologists. Radiation oncology (London, England), 10, 233. https://doi.org/10.1186/s13014-015-0548-8
  8. Roach, P. J., Francis, R., Emmett, L., Hsiao, E., Kneebone, A., Hruby, G., Eade, T., Nguyen, Q. A., Thompson, B. D., Cusick, T., McCarthy, M., Tang,